Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
406
-
Total 13F shares, excl. options
-
48.7M
-
Shares change
-
+8.35M
-
Total reported value, excl. options
-
$3.06B
-
Value change
-
+$484M
-
Put/Call ratio
-
0.99
-
Number of buys
-
222
-
Number of sells
-
-149
-
Price
-
$62.77
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q1 2022
503 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q1 2022.
CRISPR Therapeutics AG - Common Stock (CRSP) has 406 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.7M shares
of 86M outstanding shares and own 56.65% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (9.4M shares), Sumitomo Mitsui Trust Holdings, Inc. (4.62M shares), Nikko Asset Management Americas, Inc. (4.62M shares), Capital International Investors (3.6M shares), BlackRock Inc. (2.28M shares), LOOMIS SAYLES & CO L P (1.29M shares), FMR LLC (1.26M shares), VANGUARD GROUP INC (1.22M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.17M shares), and ARMISTICE CAPITAL, LLC (1.02M shares).
This table shows the top 406 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.